Search

Your selection

None

Filter by content type

Filter by content year

News

Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

April 23, 2026 - … more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA … Molecular Evolution and Serono Laboratories , where he led the development of therapies resulting in FDA approvals … more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA …
News

Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

March 12, 2026 - … women. Research demonstrated that oral vaccination led to a significant increase in norovirus-specific … women. Research demonstrated that oral vaccination led to a significant increase in norovirus-specific … women. Research demonstrated that oral vaccination led to a significant increase in norovirus-specific …
News

Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

January 15, 2026 - … 15, 2026 General Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific … demonstrate that oral vaccination of lactating women led to passive transfer of norovirus-specific antibodies to … Vaxart, Inc. Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific …
News

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 15, 2025 - … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and …
News

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

May 13, 2025 - … to May 2025 . During his tenure at AltruBio, Mr. Grasman led finance and operations and helped scale the company for … to May 2025 . During his tenure at AltruBio, Mr. Grasman led finance and operations and helped scale the company for … to May 2025 . During his tenure at AltruBio, Mr. Grasman led finance and operations and helped scale the company for …
News

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

March 20, 2025 - … 2b trial, Vaxart implemented a restructuring plan that led to an approximately 10% reduction of Vaxart’s workforce … 2b trial, Vaxart implemented a restructuring plan that led to an approximately 10% reduction of Vaxart’s workforce … 2b trial, Vaxart implemented a restructuring plan that led to an approximately 10% reduction of Vaxart’s workforce …
News

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

January 14, 2025 - … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and …
News

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

January 13, 2025 - … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and …
News

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

December 2, 2024 - … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and … received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and …
News

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

September 30, 2024 - … received under Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development … received under Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development … received under Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development …
Scroll to Top